- Brand name
- DBL Hyoscine Injection BP (Solution for injection)
- Active ingredient
- Hyoscine hydrobromide
Consumer medicine information (CMI) leaflet
Please read this leaflet carefully before you start using DBL Hyoscine Injection BP (Solution for injection).Download CMI (PDF) Download large text CMI (PDF)
What is in this leaflet
This leaflet answers some common questions about DBL™ Hyoscine Injection BP (hyoscine). It does not contain all the available information.
It does not take the place of talking to your doctor and pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you being given DBL™ Hyoscine Injection BP against the benefits this medicine is expected to have for you.
If you have any concerns about this medicine, ask your doctor or pharmacist.
Keep this leaflet in a safe place.
You may need to read it again.
What DBL™ Hyoscine Injection BP is used for
DBL™ Hyoscine Injection BP is used before surgery to make you drowsy and forgetful, and to reduce the amount of saliva and some fluids you produce in your lungs. It is also used to treat nausea and vomiting from motion sickness.
Hyoscine works by acting directly on your brain, salivary glands and air passages to reduce nerve impulses and slow down the activity of these areas.
Your doctor may have prescribed DBL™ Hyoscine Injection BP for another reason. Ask your doctor if you have any questions about why this medicine has been prescribed for you.
Before you are given DBL™ Hyoscine Injection BP
When you must not be given it
DBL™ Hyoscine Injection BP should not be given to you if:
- you have an allergy to Hyoscine.
Some of the symptoms of an allergic reaction to hyoscine may include skin rash, itching, difficulty breathing and swelling, especially of the face and throat.
- the packaging is torn or shows signs of tampering.
- the expiry date on the pack has passed.
If you are given this medicine after the expiry date has passed, it may not work as well.
- you have, or have ever had, any of the following medical conditions:
- glaucoma, a disorder where there is a build-up of pressure in the eye
- gut problems such as pyloric obstruction, paralytic ileus or inflammatory bowel disease
- enlarged prostate gland (if you are male)
- difficulty passing urine
- increased heart rate due to thyroid problems or heart failure.
Before you are given it
Your doctor must know about all the following before you are given DBL™ Hyoscine Injection BP:
- if you have or have ever had any other health problems or medical conditions, including:
- a fever
- heart problems
- liver problems
- kidney problems
- thyroid problems
- if you are pregnant or intend to become pregnant
Your doctor will discuss the risks and benefits of you being given DBL™ Hyoscine Injection BP during pregnancy.
- if you are breast-feeding or plan to breast-feed
Your doctor will discuss the risks and benefits of you being given DBL™ Hyoscine Injection BP when breast-feeding.
If you have not told your doctor about any of the above, tell them before you are given DBL™ Hyoscine Injection BP.
Taking other medicines
Tell your doctor or pharmacist if you are taking any other medicines, including medicines that you buy without a prescription from your pharmacy, supermarket or health food shop. Some medicines may interfere with DBL™ Hyoscine Injection BP. These include:
- antihistamines; medicines used to treat hayfever or allergy such as promethazine or pheniramine
- antidepressants; medicines used to treat depression such as, amitryptiline, mianserin or phenelzine
- Monoamine Oxidase (MAO) inhibitors, medicines used to treat depression
- medicines used to treat gut problems such as spasm and travel sickness, eg atropine
- medicines used to treat anxiety or to help you sleep
- some medicines used to treat mood/thought disorders, such as schizophrenia, eg chlorpromazine, fluphenazine
- belladonna, used to treat cramp or spasms
- procainamide, used to treat some heart conditions.
These medicines may be affected by DBL™ Hyoscine Injection BP, or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines. Your doctor or pharmacist has more information on medicines to be careful with or avoid while you are being given Hyoscine Injection BP.
Follow all directions given to you by your doctor or pharmacist carefully.
They may differ from the information contained in this leaflet.
If you do not understand the instructions on the box/bottle, ask your doctor or pharmacist for help.
How it is given
Hyoscine Injection BP can be given in three ways:
- as an injection into a vein
- as a deep injection into a large muscle
- as an injection under the skin.
DBL™ Hyoscine Injection BP must only be given by a doctor, nurse or other trained person.
How much is given
Your doctor will decide what dose of DBL™ Hyoscine Injection BP you will receive and how long you need to receive it for. This depends on your medical condition and other factors, such as your age.
Sometimes only a single dose of DBL™ Hyoscine Injection BP is required.
If you take too much (overdose)
As DBL™ Hyoscine Injection BP is given to you under the supervision of your doctor it is unlikely that you will receive an overdose. However, if you experience severe side effects, tell your doctor immediately, contact the Poisons Information Centre (telephone 13 11 26 in Australia, or call 0800 764 766 in New Zealand) for advice, or go to Accident and Emergency at the nearest hospital.
You may need urgent medical attention.
Symptoms of a hyoscine overdose include the side effects listed below in the “Side Effects” section, but are usually of a more severe nature.
While you are being given DBL™ Hyoscine Injection BP
Things you must do
If you are about to have any blood tests, tell your doctor that you are taking this medicine.
It may interfere with the results of some tests.
Things to be careful of
Be careful driving or operating machinery until you know how DBL™ Hyoscine Injection BP affects you.
Hyoscine may cause dizziness, drowsiness or sleepiness in some people and affect their alertness.
If this occurs, do not drive, operate machinery or do things that could be dangerous if you are not alert.
Children should be careful when riding bicycles or climbing trees.
Tell your doctor or pharmacist as soon as possible if you do not feel well while you are being given DBL™ Hyoscine Injection BP.
DBL™ Hyoscine Injection BP may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.
Do not be alarmed by this list of possible side effects.
You may not experience any of them.
Ask your doctor or pharmacist to answer any questions you may have.
Tell your doctor immediately if you notice any of the following:
- blurred vision or other eye problems, including eye pain
- mood or mental changes, such as nervousness, anxiety, confusion, paranoia or irritability
- weakness, drowsiness, restlessness or dizziness
- unco-ordination or disorientation
- memory loss
- difficulty urinating
- dry mouth
- rashes or skin redness, especially at the site of injection
- irregular, fast or slow heartbeat
- difficulty breathing
Some people may get other side effects while being given DBL™ Hyoscine Injection BP.
After being given DBL™ Hyoscine Injection BP
DBL™ Hyoscine Injection BP should be kept in a cool dry place where the temperature stays below 25°C, and should be protected from light.
What it looks like
DBL™ Hyoscine Injection BP is a clear, colourless to straw coloured solution.
DBL™ Hyoscine Injection BP contains hyoscine hydrobromide and water for injection.
It does not contain gluten, lactose, sucrose, tartrazine or any other azo dyes.
DBL™ Hyoscine Injection BP is supplied by:
Hospira Australia Pty Ltd
ABN 58 097 064 330
500 Collins Street
Melbourne VIC 3000
New Zealand Sponsor:
Hospira NZ Limited
23 Haining Street
DBL™ Hyoscine Injection BP is available in the following presentation:
400 micrograms /1 mL amp x 5 AUST R 16347
This leaflet was prepared in September 1998 and reviewed in November 2011.